Non-factor replacement therapy for Haemophilia: A current update

Massimo Franchini, Pier Mannuccio Mannucci

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

One of the most challenging issues facing us in the treatment of haemophilia is the development of alloantibodies against infused factor VIII (FVIII) or factor IX (FIX). Inhibitors render factor replacement therapy ineffective, exposing patients to an unacceptably high risk of morbidity and mortality. Besides the well-known bypassing agents (i.e. activated prothrombin complex concentrate and recombinant activated factor VII) used to treat or prevent bleeding in haemophilia patients with inhibitors, there is growing interest in a new class of therapeutic agents which act by enhancing coagulation (i.e. emicizumab) or inhibiting anticoagulant pathways (i.e. fitusiran and concizumab). This review will focus on these innovative therapies, providing an update on their current stage of clinical development.

Original languageEnglish
Pages (from-to)457-461
Number of pages5
JournalBlood Transfusion
Volume16
Issue number5
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Hemophilia A
Isoantibodies
Factor VIIa
Investigational Therapies
Factor IX
Factor VIII
Anticoagulants
Therapeutics
Hemorrhage
Morbidity
Mortality

Keywords

  • ACE910
  • Antithrombin
  • Concizumab
  • Emicizumab
  • Haemostatic agents

ASJC Scopus subject areas

  • Immunology and Allergy
  • Hematology

Cite this

Non-factor replacement therapy for Haemophilia : A current update. / Franchini, Massimo; Mannucci, Pier Mannuccio.

In: Blood Transfusion, Vol. 16, No. 5, 01.09.2018, p. 457-461.

Research output: Contribution to journalReview article

@article{a9f67d68011b44faafdced13394608d4,
title = "Non-factor replacement therapy for Haemophilia: A current update",
abstract = "One of the most challenging issues facing us in the treatment of haemophilia is the development of alloantibodies against infused factor VIII (FVIII) or factor IX (FIX). Inhibitors render factor replacement therapy ineffective, exposing patients to an unacceptably high risk of morbidity and mortality. Besides the well-known bypassing agents (i.e. activated prothrombin complex concentrate and recombinant activated factor VII) used to treat or prevent bleeding in haemophilia patients with inhibitors, there is growing interest in a new class of therapeutic agents which act by enhancing coagulation (i.e. emicizumab) or inhibiting anticoagulant pathways (i.e. fitusiran and concizumab). This review will focus on these innovative therapies, providing an update on their current stage of clinical development.",
keywords = "ACE910, Antithrombin, Concizumab, Emicizumab, Haemostatic agents",
author = "Massimo Franchini and Mannucci, {Pier Mannuccio}",
year = "2018",
month = "9",
day = "1",
doi = "10.2450/2018.0272-17",
language = "English",
volume = "16",
pages = "457--461",
journal = "Blood Transfusion",
issn = "1723-2007",
publisher = "Edizioni SIMTI",
number = "5",

}

TY - JOUR

T1 - Non-factor replacement therapy for Haemophilia

T2 - A current update

AU - Franchini, Massimo

AU - Mannucci, Pier Mannuccio

PY - 2018/9/1

Y1 - 2018/9/1

N2 - One of the most challenging issues facing us in the treatment of haemophilia is the development of alloantibodies against infused factor VIII (FVIII) or factor IX (FIX). Inhibitors render factor replacement therapy ineffective, exposing patients to an unacceptably high risk of morbidity and mortality. Besides the well-known bypassing agents (i.e. activated prothrombin complex concentrate and recombinant activated factor VII) used to treat or prevent bleeding in haemophilia patients with inhibitors, there is growing interest in a new class of therapeutic agents which act by enhancing coagulation (i.e. emicizumab) or inhibiting anticoagulant pathways (i.e. fitusiran and concizumab). This review will focus on these innovative therapies, providing an update on their current stage of clinical development.

AB - One of the most challenging issues facing us in the treatment of haemophilia is the development of alloantibodies against infused factor VIII (FVIII) or factor IX (FIX). Inhibitors render factor replacement therapy ineffective, exposing patients to an unacceptably high risk of morbidity and mortality. Besides the well-known bypassing agents (i.e. activated prothrombin complex concentrate and recombinant activated factor VII) used to treat or prevent bleeding in haemophilia patients with inhibitors, there is growing interest in a new class of therapeutic agents which act by enhancing coagulation (i.e. emicizumab) or inhibiting anticoagulant pathways (i.e. fitusiran and concizumab). This review will focus on these innovative therapies, providing an update on their current stage of clinical development.

KW - ACE910

KW - Antithrombin

KW - Concizumab

KW - Emicizumab

KW - Haemostatic agents

UR - http://www.scopus.com/inward/record.url?scp=85048135337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048135337&partnerID=8YFLogxK

U2 - 10.2450/2018.0272-17

DO - 10.2450/2018.0272-17

M3 - Review article

AN - SCOPUS:85048135337

VL - 16

SP - 457

EP - 461

JO - Blood Transfusion

JF - Blood Transfusion

SN - 1723-2007

IS - 5

ER -